Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma



Status:Active, not recruiting
Conditions:Lymphoma
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:March 2010
End Date:March 2016

Use our guide to learn which trials are right for you!

Phase II Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma

The goal of this multi-center Phase II study is to add bortezomib to the highly active
regimen of bendamustine and rituximab. In this study, bortezomib will be administered on a
weekly schedule (Days 1, 8, 15) and will be added to bendamustine/rituximab given in 4-week
cycles. This combination uses the standard bendamustine dosing schedule, and is more
convenient than the 5-week regimen of these 3 drugs currently being studied.


Inclusion Criteria:

1. Histologically-confirmed indolent lymphoma by the World Health Organization (WHO)
classification. The biopsy must fulfill one of the following criteria:

- Follicular lymphoma, grade 1 or 2

- Marginal zone lymphoma

- Small lymphocytic lymphoma (circulating lymphocyte count must be <5,000)

- Lymphoplasmacytic lymphoma

2. At least one of the following criteria must be met:

- Presence of any symptoms related to lymphoma. These can include classic
B-symptoms (fever [>38°C] of unclear etiology, night sweats, weight loss of
greater than 10% within the prior 6 months) or other lymphoma-related symptoms
(fatigue, pain, etc.).

- Large tumor mass (bulky disease) characterized by lymphomas with a diameter of
more than 3 cm in three or more regions or by a lymphoma with a diameter >7 cm
in one region

- Presence of lymphoma-related complications, including narrowing of ureters or
bile ducts, tumor-related compression of a vital organ, lymphoma-induced pain,
cytopenias related to lymphoma/leukemia, splenomegaly, pleural effusions, or
ascites

- Hyperviscosity syndrome due to monoclonal gammopathy

3. The lymph node biopsy or other lymphoma pathology specimen has CD20+ B-cells.

4. Ann-Arbor Stage 2 (non-contiguous), 3, or 4 disease.

5. No previous systemic treatment for lymphoma. Patients may have had a single course of
radiation therapy to a limited field (i.e., not exceeding two adjacent lymph node
regions).

6. The patient has bidimensionally measurable disease with at least 1 lesion measuring
≥2.0 cm in a single dimension, and the field was not previously radiated.

7. An Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2.

8. Adequate hematologic function ≤7 days prior to start of study treatment:

- Hemoglobin ≥10.0 g/dl

- Absolute neutrophil count (ANC) ≥1000/µL

- Platelet count ≥75,000/µL. If low counts are attributable to bone marrow
infiltration or hypersplenism due to lymphoma, ANC must be ≥750/µL and platelets
≥50,000/µL.

9. Calculated or measured creatinine clearance ≥30 mL/min ≤7 days of study enrollment
(using Cockcroft-Gault method).

10. Adequate hepatic function (≤2.5 x upper limit of normal [ULN] for alanine
aminotransferase [ALT], aspartate aminotransferase [AST], and alkaline phosphatase
and total bilirubin within normal limits).

11. Patients must be ≥18 years of age.

12. Women of childbearing potential must agree to use a medically acceptable method of
birth control (e.g., a hormonal contraceptive, intra-uterine device, diaphragm with
spermicide, condom with spermicide, or abstinence) for the duration of the study and
for 12 months after their last dose of rituximab. Men must use an acceptable
method/form of contraception for the duration of treatment and for 3 months after the
end of treatment.

13. Patients must be able to understand the investigational nature of this study and give
written informed consent prior to study entry.

Exclusion Criteria:

1. The patient has chronic lymphocytic leukemia.

2. The patient has transformed lymphoma.

3. History of, or clinically apparent, central nervous system (CNS) lymphoma or
leptomeningeal lymphoma.

4. The patient has received corticosteroids for treatment of lymphoma. Chronic, low-dose
corticosteroids (e.g., prednisone ≤20 mg/day) are allowed for treatment uses other
than lymphoma or complications of lymphoma.

5. Peripheral neuropathy ≥ CTCAE v3.0 grade 2, ≤14 days of study enrollment.

6. Myocardial infarction ≤6 months prior to study enrollment or New York Heart
Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe
uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute
ischemia or active conduction system abnormalities. Prior to study entry, ECG
abnormalities at screening must be documented as not medically relevant.

7. History of solid organ transplantation, or post-transplant lymphoproliferative
disorder.

8. Patients with known history of hepatitis B or hepatitis C infection. Hepatitis B
surface antigen must be tested.

9. The patient has known human immunodeficiency virus (HIV) infection.

10. Active, clinically serious infection > grade 2. Patients may be eligible upon
resolution of the infection.

11. Female patient is pregnant or breast-feeding. Confirmation that female patients of
childbearing potential are not pregnant must be established by a negative serum
pregnancy test ≤7 days prior to the start of treatment.

12. Known hypersensitivity to bendamustine, bortezomib, boron, mannitol, or rituximab.

13. Concomitant active malignancy requiring therapy.

14. Diagnosis or treatment for another malignancy within 3 years of enrollment, with the
exception of complete resection of basal cell carcinoma or squamous cell carcinoma of
the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy.

15. Treatment with other investigational agents ≤14 days prior to study enrollment.

16. Any other disease(s), psychiatric condition, metabolic dysfunction, or findings from
a physical examination or clinical laboratory test result that would cause reasonable
suspicion of a disease or condition, that contraindicates the use of study drugs,
that may increase the risk associated with study participation, that may affect the
interpretation of the results, or that would make the patient inappropriate for this
study.
We found this trial at
20
sites
Jonesboro, Arkansas 72401
?
mi
from
Jonesboro, AR
Click here to add this to my saved trials
Baton Rouge, Louisiana 70806
?
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
6410 Rockledge Dr #660
Bethesda, Maryland 20817
(301) 571-0019
Center for Cancer & Blood Disorders Widely recognized for its compassionate, expert care, the Center...
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
Chattanooga, Tennessee 37404
?
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Chesterfield, Missouri 63017
?
mi
from
Chesterfield, MO
Click here to add this to my saved trials
5053 Wooster Rd
Cincinnati, Ohio 45226
(513) 751-2273
Oncology Hematology Care Our more than 60 physicians and advanced practice providers throughout neighborhood offices...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Ft. Lauderdale, Florida 33308
?
mi
from
Ft. Lauderdale, FL
Click here to add this to my saved trials
Ft. Myers, Florida 33916
?
mi
from
Ft. Myers, FL
Click here to add this to my saved trials
743 Spring St NE
Gainesville, Georgia 30501
770-219-9000
Northeast Georgia Medical Center Northeast Georgia Health System (NGHS) is a not-for-profit community health system...
?
mi
from
Gainesville, GA
Click here to add this to my saved trials
25 Michigan St. NE, Suite 3100
Grand Rapids, Michigan 49503
(616) 391-1230
Grand Rapids Clinical Oncology Program GRCOP initially formed to develop community cancer patient management guidelines....
?
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Lawton, Oklahoma 73505
?
mi
from
Lawton, OK
Click here to add this to my saved trials
Louisville, Kentucky 40207
?
mi
from
Louisville, KY
Click here to add this to my saved trials
Morristown, New Jersey 07960
?
mi
from
Morristown, NJ
Click here to add this to my saved trials
250 25th Ave N, Ste 100
Nashville, Tennessee 37023
615-320-5090
Tennessee Oncology, PLLC Since 1976 Tennessee Oncology has been providing quality cancer care. In 2013,...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Portsmouth, New Hampshire 03801
?
mi
from
Portsmouth, NH
Click here to add this to my saved trials
?
mi
from
Skokie, IL
Click here to add this to my saved trials
Terre Haute, Indiana 47802
?
mi
from
Terre Haute, IN
Click here to add this to my saved trials
Wheeling, West Virginia 26003
?
mi
from
Wheeling, WV
Click here to add this to my saved trials